6-K 1 a7756h.htm RESULT OF AGM a7756h
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of May 2025
 
Commission File Number 001-15170
 
 
GSK plc
(Translation of registrant's name into English)
 
 
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
GSK plc
 
Results of 25th Annual General Meeting
 
GSK plc ('GSK') held a hybrid Annual General Meeting ('AGM') at 2.30pm on Wednesday 7 May 2025 at The Landmark London, 222 Marylebone Road, London, NW1 6JQ. Shareholders were able to join the meeting in person or virtually via the Lumi AGM website and Zoom.
 
All valid proxy votes (whether submitted electronically or in hard copy form) were included in the poll taken at the meeting.
 
All 25 resolutions were passed and decided upon by a poll. The table below shows the results for each resolution. The full text of the resolutions is contained in the Notice of AGM published on 24 March 2025, which is available on GSK's website at www.gsk.com.
 
Resolution
Total votes for(1)(2)
%
Total votes against(2)
%
Total votes cast
% of Issued Share Capital voted(3)
Votes withheld(4)
1
Receive and adopt the 2024 Annual Report
3,031,647,740
99.82
5,472,209
0.18
3,037,119,949
73.91%
12,204,390
2
Approve the Annual report on remuneration 
2,810,183,626
92.46
229,176,108
7.54
3,039,359,734
73.97%
9,979,421
3
Approve the Remuneration policy
2,786,567,742
93.10
206,384,696
6.90
2,992,952,438
72.84%
56,376,703
4
Election of Dr Gavin Screaton
3,040,206,238
99.89
3,385,136
0.11
3,043,591,374
74.07%
5,719,426
5
Re-election of Sir Jonathan Symonds
2,947,917,394
98.40
48,075,530
1.60
2,995,992,924
72.91%
53,319,043
6
Re-election of Dame Emma Walmsley
3,038,248,728
99.82
5,613,533
0.18
3,043,862,261
74.08%
5,444,311
7
Re-election of Julie Brown
3,034,344,765
99.69
9,515,889
0.31
3,043,860,654
74.08%
5,460,463
8
Re-election of Elizabeth McKee Anderson
2,941,679,748
96.64
102,161,424
3.36
3,043,841,172
74.08%
5,465,676
9
Re-election of Charles Bancroft
2,956,308,387
97.13
87,450,752
2.87
3,043,759,139
74.07%
5,553,709
10
Re-election of Dr Hal Barron
3,039,339,475
99.85
4,466,176
0.15
3,043,805,651
74.08%
5,489,801
11
Re-election of Dr Anne Beal
2,955,431,838
97.09
88,492,673
2.91
3,043,924,511
74.08%
5,388,566
12
Re-election of Wendy Becker
2,933,164,994
96.36
110,745,350
3.64
3,043,910,344
74.08%
5,400,009
13
Re-election of Dr Harry C Dietz
3,039,383,688
99.86
4,369,000
0.14
3,043,752,688
74.07%
5,560,851
14
Re-election of Dr Jeannie Lee
3,039,577,387
99.86
4,161,377
0.14
3,043,738,764
74.07%
5,574,652
15
Re-election of Dr Vishal Sikka
3,038,858,707
99.84
4,756,490
0.16
3,043,615,197
74.07%
5,688,803
16
Re-appointment of the auditor
3,025,673,462
99.89
3,223,574
0.11
3,028,897,036
73.71%
20,430,064
17
Remuneration of the auditor
3,039,931,435
99.88
3,782,302
0.12
3,043,713,737
74.07%
5,591,584
18
Authority for the company to make donations to political organisations and incur political expenditure
2,946,755,927
99.01
29,581,561
0.99
2,976,337,488
72.43%
72,977,673
19
Authority to allot shares
2,899,903,495
95.30
143,133,156
4.70
3,043,036,651
74.06%
6,282,441
20
Disapplication of pre-emption rights - general power(5)
2,941,521,597
96.72
99,811,731
3.28
3,041,333,328
74.02%
7,942,085
21
Disapplication of pre-emption rights - in connection with an acquisition or specified capital investment(5)
2,962,038,875
97.39
79,351,038
2.61
3,041,389,913
74.02%
7,904,048
22
Authority for the company to purchase its own shares(5)
3,036,538,826
99.83
5,280,936
0.17
3,041,819,762
74.03%
7,499,989
23
Exemption from statement of senior statutory auditor's name
3,022,840,749
99.74
7,951,051
0.26
3,030,791,800
73.76%
18,502,136
24
Authority for reduced notice of a general meeting other than an AGM(5)
2,863,892,275
94.11
179,242,127
5.89
3,043,134,402
74.06%
6,172,307
25
Approve the adoption of the GSK Share Value Plan
2,972,805,515
99.56
13,033,137
0.44
2,985,838,652
72.67%
63,503,752
 
Notes:
 
(1)    The "for" votes include those giving the Chair discretion.
(2)    Votes "for" and "against" are expressed as a percentage of the total votes cast.
(3)    The Company's issued share capital as at 2 May 2025 consisted of 4,109,037,095 shares of 31 ¼ pence each ('Ordinary Shares') excluding Ordinary Shares held in Treasury. Every shareholder has one vote for every Ordinary Share held.
(4)    A "vote withheld" is not a vote in law and is not counted in the calculation of the proportion of votes "for" or "against" a resolution.
(5)    Indicates Special Resolutions requiring a 75% majority of votes cast.
 
The following table provides further information on participation in the AGM:
 
 
GSK's 25th AGM
(Hybrid meeting)
(2025)
GSK's 24th AGM
(Hybrid meeting)
(2024)
Issued share capital (excluding Treasury Shares)
4,109,037,095
4,314,108,510
Total votes cast and votes withheld lodged as a % of GSK's issued share capital (excluding Treasury Shares)
74.21%
73.11%
Total shareholder population
86,241
60,448
Total number of proxies lodged
3,743
2,886
Number of shareholders in attendance
130 in person
25 participated virtually
125 in person
38 participated virtually
% of shareholders who lodged proxies
4.34%
4.77%
 
The above poll results will shortly be available on the company's website at www.gsk.com.
 
In accordance with Listing Rule 6.4.2 of the Financial Conduct Authority's (FCA) Listing Rules, a copy of the resolutions, other than those concerning ordinary business, will be submitted to the FCA and will, in due course, be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism
 
V A Whyte
Company Secretary
7 May 2025

 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
GSK plc
 
(Registrant)
 
 
Date: May 07, 2025
 
 
 
 
By:/s/ VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GSK plc